Redundancy and compensation provide robustness to biological systems but may contribute to therapy resistance. Both tumor-associated macrophages (TAMs) and Foxp3+ regulatory T (Treg) cells promote tumor progression by limiting antitumor immunity. Here we show that genetic ablation of CSF1 in colorectal cancer cells reduces the influx of immunosuppressive CSF1R+ TAMs within tumors. This reduction in CSF1-dependent TAMs resulted in increased CD8+ T cell attack on tumors, but its effect on tumor growth was limited by a compensatory increase in Foxp3+ Treg cells. Similarly, disruption of Treg cell activity through their experimental ablation produced moderate effects on tumor growth and was associated with elevated numbers of CSF1R+ TAMs. Importantly, codepletion of CSF1R+ TAMs and Foxp3+ Treg cells resulted in an increased influx of CD8+ T cells, augmentation of their function, and a synergistic reduction in tumor growth. Further, inhibition of Treg cell activity either through systemic pharmacological blockade of PI3Kδ, or its genetic inactivation within Foxp3+ Treg cells, sensitized previously unresponsive solid tumors to CSF1R+ TAM depletion and enhanced the effect of CSF1R blockade. These findings identify CSF1R+ TAMs and PI3Kδ-driven Foxp3+ Treg cells as the dominant compensatory cellular components of the immunosuppressive tumor microenvironment, with implications for the design of combinatorial immunotherapies.
David Gyori, Ee Lyn Lim, Francis M. Grant, Dominik Spensberger, Rahul Roychoudhuri, Stephen J. Shuttleworth, Klaus Okkenhaug, Len R. Stephens, Phillip T. Hawkins
Title and authors | Publication | Year |
---|---|---|
Ad-SGE-DKK3 gene therapy against resistance to immune checkpoint blockade in malignant mesothelioma
Hee-Jin Jang, Meera Patel, Daniel Y Wang, Sung Kang, Jong Choi, Monica Vilchis, Claire Lee, Ji Seon Shim, Priyanka Ranchod, Sonali Mitra, Allen Kuncheria, William Hudson, Peter Jindra, Veronica Rosen, Maheshwari Ramineni, Ernest Camp, Farrah Kheradmand, R. Ripley, Shawn Groth, Hyun-Sung Lee, Bryan Burt |
Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 |
Mitochondrial DNA lineages determine tumor progression through T cell reactive oxygen signaling
Yardeni T, Olali AZ, Chen HW, Wang L, Halton JA, Zenab A, Morrow R, Butic A, Murdock DG, Waymire KG, MacGregor GR, Boursi B, Beier UH, Hancock WW, Wallace DC |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation
Huang T, Wei L, Zhou H, Liu J |
Cancer Medicine | 2025 |
Myeloid cells: key players in tumor microenvironments.
Hua Q, Li Z, Weng Y, Wu Y, Zheng L |
Frontiers of medicine | 2025 |
Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy.
Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L |
Journal of experimental & clinical cancer research : CR | 2025 |
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives
Fu R, Hu R, Li W, Lv X, Zhao H, Li F |
Frontiers in Immunology | 2025 |
Macrophages in prostate cancer: dual roles in tumor progression and immune evasion
Liu R, Lu J, Liu J, Liao Y, Guo Y, Shi P, Wang Z, Wang H, Lai J |
Journal of Translational Medicine | 2025 |
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
Rosenbaum E, Seier K, Bradic M, Movva S, Kelly CM, Dickson MA, Keohan ML, Gounder MM, Chi P, Nacev BA, Chan JE, Avutu V, Biniakewitz M, Jasnani S, Duchemin M, Desir R, Wong P, Erinjeri J, Hwang S, Antonescu CR, Qin LX, Tap WD, D\u2019Angelo SP |
ESMO Open | 2025 |
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype
Sharma N, Fan X, Atolagbe OT, Ge Z, Dao KN, Sharma P, Allison JP |
Journal of Experimental Medicine | 2024 |
De novo steroidogenesis in tumor cells drives bone metastasis and osteoclastogenesis
Sandor LF, Huh JB, Benko P, Hiraga T, Poliska S, Dobo-Nagy C, Simpson JP, Homer NZ, Mahata B, Gyori DS |
Cell Reports | 2024 |
The ins and outs of microglial cells in brain health and disease
Pallarés-Moratalla C, Bergers G |
Frontiers in immunology | 2024 |
Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip
Suryavanshi P, Bodas D |
Nanotheranostics | 2024 |
Defining mesenchymal stem/stromal cell-induced myeloid-derived suppressor cells using single-cell transcriptomics
Lee HJ, Choi YR, Ko JH, Ryu JS, Oh JY |
Molecular Therapy | 2024 |
The genomic landscape of the immune system in lung cancer: present insights and continuing investigations
Roshan-Zamir M, Khademolhosseini A, Rajalingam K, Ghaderi A, Rajalingam R |
Frontiers in Genetics | 2024 |
The protective role of GATA6+ pericardial macrophages in pericardial inflammation
Hughes DM, Won T, Talor MV, Kalinoski HM, Jurčová I, Szárszoi O, Stříž I, Čurnová L, Bracamonte-Baran W, Melenovský V, Čiháková D |
iScience | 2024 |
Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells
Zou D, Xin X, Xu Y, Xu H, Huang L, Xu T |
Heliyon | 2024 |
CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker
Zhu Z, Liu H, Fu H, Luo Y, Chen B, Wu X, Sun A, Zhang F, Wang T |
Scientific Reports | 2024 |
CSF1 mediating 3-hydroxyhexanoate in endometrial cancer: a Mendelian randomization study
Jiazhen H, Bozhen F |
Archives of Medical Science : AMS | 2024 |
Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer
Wang X, Yin X, Li Y, Zhang S, Hu M, Wei M, Li Z |
Journal of Nanobiotechnology | 2024 |
Non-invasive imaging of tumor-associated macrophages under anti-PD1 treatment in a murine model of melanoma
Gyo Jeong Gu, Hyewon Chung, Ji Yong Park, Ran Yoo, Hyung Im, Hongyoon Choi, Yun-Sang Lee, Seung Seok |
Journal of nanobiotechnology | 2023 |
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials
Wang Z, Zhou H, Xu J, Wang J, Niu T |
Frontiers in immunology | 2023 |
Interaction of tumor-associated macrophages with stromal and immune components in solid tumors: Research progress (Review)
Kazakova A, Sudarskikh T, Kovalev O, Kzhyshkowska J, Larionova I |
International journal of oncology | 2023 |
The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches
Kalluri AL, Shah PP, Lim M |
International journal of molecular sciences | 2023 |
Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer
Alshaebi F, Safi M, Algabri YA, Al-Azab M, Aldanakh A, Alradhi M, Reem A, Zhang C |
Frontiers in Oncology | 2023 |
Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma
Zhang W, Jiang X, Zou Y, Yuan L, Wang X |
Frontiers in pharmacology | 2023 |
Therapeutic targeting of tumour myeloid cells.
Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP |
Nature reviews. Cancer | 2023 |
Ecological niches for colorectal cancer stem cell survival and thrival
Che J, Yu S |
Frontiers in Oncology | 2023 |
Role of tumor-associated macrophages in common digestive system malignant tumors
Shen Y, Chen JX, Li M, Xiang Z, Wu J, Wang YJ |
World journal of gastrointestinal oncology | 2023 |
Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies.
Glasner A, Rose SA, Sharma R, Gudjonson H, Chu T, Green JA, Rampersaud S, Valdez IK, Andretta ES, Dhillon BS, Schizas M, Dikiy S, Mendoza A, Hu W, Wang ZM, Chaudhary O, Xu T, Mazutis L, Rizzuto G, Quintanal-Villalonga A, Manoj P, de Stanchina E, Rudin CM, Pe'er D, Rudensky AY |
Nature Immunology | 2023 |
Spatiotemporal Characterization of Human Early Intervertebral Disc Formation at Single‐Cell Resolution
Zhou T, Chen Y, Liao Z, Zhang L, Su D, Li Z, Yang X, Ke X, Liu H, Chen Y, Weng R, Shen H, Xu C, Wan Y, Xu R, Su P |
Advanced Science | 2023 |
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.
Al-Sudani H, Ni Y, Jones P, Karakilic H, Cui L, Johnson LDS, Rose PG, Olawaiye A, Edwards RP, Uger RA, Lin GHY, Mahdi H |
npj Precision Oncology | 2023 |
Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors.
Matos AI, Peres C, Carreira B, Moura LIF, Acúrcio RC, Vogel T, Wegener E, Ribeiro F, Afonso MB, Santos FMF, Martínez-Barriocanal Á, Arango D, Viana AS, Góis PMP, Silva LC, Rodrigues CMP, Graca L, Jordan R, Satchi-Fainaro R, Florindo HF |
2023 | |
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Djureinovic D, Weiss SA, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto AL, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech SM, Bosenberg M, Jilaveanu LB, Kluger HM |
Molecular Cancer | 2023 |
Targeting Myeloid-Derived Suppressor Cell Trafficking as a Novel Immunotherapeutic Approach in Microsatellite Stable Colorectal Cancer
Johnson B |
Cancers | 2023 |
FOXP3-regulated lncRNA NONHSAT136151 promotes colorectal cancer progression by disrupting QKI interaction with target mRNAs.
Huang H, Liang X, Wu W, Yuan T, Chen Z, Wang L, Wu Z, Zhang T, Yang K, Wen K |
Journal of Cellular and Molecular Medicine | 2023 |
CSF1/CSF1R signaling mediates malignant pleural effusion formation
Chrysavgi Kosti, Photene Vaitsi, Apostolos Pappas, Marianthi Iliopoulou, Katherina Psarra, Sophia Magkouta, Ioannis Kalomenidis. |
JCI Insight | 2022 |
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
M Prasad, J Zorea, S Jagadeeshan, A Shnerb, S Mathukkada, J Bouaoud, L Michon, O Novoplansky, M Badarni, L Cohen, K Yegodayev, S Tzadok, B Rotblat, L Brezina, A Mock, A Karabajakian, J Fayette, I Cohen, T Cooks, I Allon, O Dimitstein, B Joshua, D Kong, E Voronov, M Scaltriti, Y Carmi, C Conde-Lopez, J Hess, I Kurth, L Morris, P Saintigny, M Elkabets |
Journal for ImmunoTherapy of Cancer | 2022 |
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
C Martori, L Sanchez-Moral, T Paul, J Pardo, A Font, V de Porras, M Sarrias |
Cancers | 2022 |
Tissue Resident Foxp3+ Regulatory T Cells: Sentinels and Saboteurs in Health and Disease
J Lee, D Kim, B Min |
Frontiers in immunology | 2022 |
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
N Kumari, S Choi |
Journal of Experimental & Clinical Cancer Research | 2022 |
Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers
D Wu, X Liu, J Mu, J Yang, F Wu, H Zhou |
Biomolecules | 2022 |
Role of macrophages in tumor progression and therapy (Review)
Y Xu, X Wang, L Liu, J Wang, J Wu, C Sun |
International journal of oncology | 2022 |
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Q Wang, J Bergholz, L Ding, Z Lin, S Kabraji, M Hughes, X He, S Xie, T Jiang, W Wang, J Zoeller, H Kim, T Roberts, P Konstantinopoulos, U Matulonis, D Dillon, E Winer, N Lin, J Zhao |
Nature Communications | 2022 |
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A |
Journal for ImmunoTherapy of Cancer | 2022 |
Aging Leads to Increased Monocytes and Macrophages With Altered CSF-1 Receptor Expression and Earlier Tumor-Associated Macrophage Expansion in Murine Mesothelioma
Duong L, Pixley FJ, Nelson DJ, Jackaman C |
2022 | |
Assessment of the TGFB1 gene expression and methylation status of the promoter region in patients with colorectal cancer
Wodziński D, Wosiak A, Pietrzak J, Świechowski R, Kordek R, Balcerczak E |
Scientific Reports | 2022 |
CAR T-Cell Targeting of Macrophage Colony-Stimulating Factor Receptor
Achkova DY, Beatson RE, Maher J |
Cells | 2022 |
Targeting IL-34/MCSF-1R Axis in Colon Cancer.
Monteleone G, Maresca C, Colella M, Pacifico T, Congiu D, Troncone E, Marafini I |
Frontiers in immunology | 2022 |
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies.
Belli C, Antonarelli G, Repetto M, Boscolo Bielo L, Crimini E, Curigliano G |
Cancers | 2022 |
Regulatory T Cells in Pancreatic Cancer: Of Mice and Men
Mota Reyes C, Demir E, Çifcibaşı K, Istvanffy R, Friess H, Demir IE |
Cancers | 2022 |
Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion.
Lauder SN, Smart K, Bart VMT, Pires A, Scott J, Milutinovic S, Godkin A, Vanhaesebroeck B, Gallimore A |
British Journal of Cancer | 2022 |
Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages
Zhu M, Bai L, Liu X, Peng S, Xie Y, Bai H, Yu H, Wang X, Yuan P, Ma R, Lin J, Wu L, Huang M, Li Y, Luo Y |
Journal for ImmunoTherapy of Cancer | 2022 |
Tumor Cell-Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer.
Chen H, Cresswell GM, Libring S, Ayers MG, Miao J, Zhang ZY, Solorio L, Ratliff TL, Wendt MK |
2022 | |
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
J Yeung, V Yaghoobi, D Miyagishima, MD Vesely, T Zhang, T Badri, A Nassar, X Han, MF Sanmamed, M Youngblood, M Peyre, M Kalamarides, DL Rimm, M Gunel, L Chen |
Neuro-Oncology | 2021 |
The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)
C Barca, C Foray, S Hermann, U Herrlinger, I Remory, D Laoui, M Schäfers, OM Grauer, B Zinnhardt, AH Jacobs |
Frontiers in immunology | 2021 |
Targeting tumor-associated macrophages to synergize tumor immunotherapy
X Xiang, J Wang, D Lu, X Xu |
Signal Transduction and Targeted Therapy | 2021 |
Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer
YW Choi, YH Kim, SY Oh, KW Suh, YS Kim, GY Lee, JE Yoon, SS Park, YK Lee, YJ Park, HS Kim, SH Park, JH Kim, TJ Park |
Advanced Science | 2021 |
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Y Ni, X Zhou, J Yang, H Shi, H Li, X Zhao, X Ma |
Frontiers in Cell and Developmental Biology | 2021 |
PI3K inhibitors are finally coming of age
B Vanhaesebroeck, MW Perry, JR Brown, F André, K Okkenhaug |
Nature Reviews Drug Discovery | 2021 |
Immune Therapy Resistance and Immune Escape of Tumors
B Seliger, C Massa |
Cancers | 2021 |
Lumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma
Y Zang, Q Dong, Y Lu, K Dong, R Wang, Z Liang |
Aging | 2021 |
CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
SF Magkouta, PC Vaitsi, AG Pappas, M Iliopoulou, CN Kosti, K Psarra, IT Kalomenidis |
Cancers | 2021 |
Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation
A Piatakova, I Polakova, J Smahelova, SD Johari, J Nunvar, M Smahel |
Cancers | 2021 |
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment
SA OBrien, J Orf, KM Skrzypczynska, H Tan, J Kim, J DeVoss, B Belmontes, JG Egen |
Cancer Immunology, Immunotherapy | 2021 |
CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function
SK Whiteside, FM Grant, DS Gyori, AG Conti, CJ Imianowski, P Kuo, R Nasrallah, F Sadiyah, SA Lira, F Tacke, RL Eil, OT Burton, J Dooley, A Liston, K Okkenhaug, J Yang, R Roychoudhuri |
Immunology | 2021 |
TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma
EY Lee, M Kim, BK Choi, DH Kim, I Choi, HJ You |
Molecules and Cells | 2021 |
Transcription Factor c-Maf Is A Checkpoint that Programs Macrophages in Lung Cancer
Min Liu, Zan Tong, Chuanlin Ding, Fengling Luo, Shouzhen Wu, Caijun Wu, Sabrin Albeituni, Liqing He, Xiaoling Hu, David Tieri, Eric C. Rouchka, Michito Hamada, Satoru Takahashi, Andrew A. Gibb, Goetz Kloecker, Huang-Ge Zhang, Michael Bousamra, Bradford G. Hill, Xiang Zhang, Jun Yan |
Journal of Clinical Investigation | 2020 |
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
N Hama, T Kobayashi, N Han, F Kitagawa, N Kajihara, R Otsuka, H Wada, H Lee, H Rhee, Y Hasegawa, H Yagita, M Baghdadi, K Seino |
iScience | 2020 |
Osteoclast Signal Transduction During Bone Metastasis Formation
DS Győri, A Mócsai |
Frontiers in Cell and Developmental Biology | 2020 |
CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model
IL Tan, RD Arifa, H Rallapalli, V Kana, Z Lao, RM Sanghrajka, NS Bayin, A Tanne, A Wojcinski, A Korshunov, N Bhardwaj, M Merad, DH Turnbull, JJ Lafaille, AL Joyner |
Oncogene | 2020 |
Exosomal MicroRNAs as Mediators of Cellular Interactions Between Cancer Cells and Macrophages
Y Kwon, M Kim, Y Kim, HS Jung, D Jeoung |
Frontiers in immunology | 2020 |
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
SN Lauder, K Smart, V Kersemans, D Allen, J Scott, A Pires, S Milutinovic, M Somerville, S Smart, P Kinchesh, E Lopez-Guadamillas, E Hughes, E Jones, M Scurr, A Godkin, LS Friedman, B Vanhaesebroeck, A Gallimore |
Journal for ImmunoTherapy of Cancer | 2020 |
Carcinogenesis of Pancreatic Ductal Adenocarcinoma
P Storz, HC Crawford |
Gastroenterology | 2020 |
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
AR Razak, JM Cleary, V Moreno, M Boyer, EC Aller, W Edenfield, J Tie, RD Harvey, A Rutten, MA Shah, AJ Olszanski, D Jäger, N Lakhani, DP Ryan, E Rasmussen, G Juan, H Wong, N Soman, MA Smit, D Nagorsen, KP Papadopoulos |
Journal for ImmunoTherapy of Cancer | 2020 |
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
KA Autio, CA Klebanoff, D Schaer, JS Kauh, SF Slovin, M Adamow, VS Blinder, M Brahmachary, M Carlsen, E Comen, DC Danila, TN Doman, JC Durack, JJ Fox, JS Gluskin, DM Hoffman, S Kang, P Kang, J Landa, PF McAndrew, S Modi, MJ Morris, R Novosiadly, DE Rathkopf, R Sanford, SC Chapman, CM Tate, D Yu, P Wong, HL McArthur |
Clinical cancer research | 2020 |
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
NS Jahchan, AM Mujal, JL Pollack, M Binnewies, V Sriram, L Reyno, MF Krummel |
Frontiers in immunology | 2019 |
Blocking inflammation to improve immunotherapy of advanced cancer
A Macciò, C Madeddu |
Immunology | 2019 |
PI 3K δ is a Treg target in cancer immunotherapy
EL Lim, K Okkenhaug |
Immunology | 2019 |
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
D Hermel, D Sigal |
Journal of Personalized Medicine | 2019 |
Macrophage-Mediated Subversion of Anti-Tumour Immunity
V Quaranta, MC Schmid |
Cells | 2019 |
Phosphoinositide-3-kinase δ inhibition promotes anti-tumour responses but antagonizes checkpoint inhibitors
Ee Lyn Lim, Fiorella M Cugliandolo, Dalya R Rosner, David Győri, Rahul Roychoudhuri, Klaus Okkenhaug |
JCI Insight | 2018 |